Secondary stroke prevention

The Lancet Neurology

Volumn 13, Issue 2, 2014, Pages 178-194

  Hankey, Graeme J ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIOXIDANT; ANTITHROMBOCYTIC AGENT; APIXABAN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CILOSTAZOL; CLOPIDOGREL; DABIGATRAN; DIPYRIDAMOLE; DIURETIC AGENT; EZETIMIBE; FOLIC ACID; INSULIN; LAROPIPRANT; NICOTINIC ACID; ORAL ANTIDIABETIC AGENT; RIVAROXABAN; SIMVASTATIN; TERUTROBAN; THROMBIN INHIBITOR; TRIFLUSAL; UNINDEXED DRUG; VORAPAXAR; WARFARIN;

ADD ON THERAPY; ANTICOAGULATION; BLEEDING; BLOOD PRESSURE REGULATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CAROTID ARTERY DISEASE; CAROTID ARTERY STENTING; CAROTID ENDARTERECTOMY; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; DIABETES MELLITUS; DIFFUSION WEIGHTED IMAGING; EVIDENCE BASED MEDICINE; EXERCISE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; HYPERTENSION; LIFESTYLE MODIFICATION; LOADING DRUG DOSE; META ANALYSIS (TOPIC); MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SCORING SYSTEM; SECONDARY PREVENTION; SINGLE DRUG DOSE; SODIUM RESTRICTION; TRANSIENT ISCHEMIC ATTACK; TREATMENT INDICATION;

HUMANS; RECURRENCE; SECONDARY PREVENTION; STROKE;

EID: 84892550381     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(13)70255-2     Document Type: Review

References (173)

1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2095-2128.
2. Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2197-2223.
3. Hankey GJ Ischaemic stroke-prevention is better than cure. J R Coll Physicians Edinb 2010, 40:56-63.
4. Rothwell PM, Coull AJ, Giles MF, et al. Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet 2004, 363:1925-1933. the Oxford Vascular Study.
5. Luengo-Fernandez R, Gray AM, Rothwell PM A population-based study of hospital care costs during 5 years after transient ischemic attack and stroke. Stroke 2012, 43:3343-3351. the Oxford Vascular Study.
6. Schwamm LH, Fonarow GC, Reeves MJ, et al. Get with the guidelines-stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack. Circulation 2009, 119:107-115.
7. Chandratheva A, Mehta Z, Geraghty OC, Marquardt L, Rothwell PM Population-based study of risk and predictors of stroke in the first few hours after a TIA. Neurology 2009, 72:1941-1947. the Oxford Vascular Study.
8. Giles MF, Rothwell PM Risk of stroke early after transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol 2007, 6:1063-1072.
9. Wang Y, Wang Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013, 369:11-19. the CHANCE investigators.
10. Rothwell PM, Giles MF, Flossmann E, et al. A simple score (ABCD) to identify individuals at high early risk of stroke after transient ischaemic attack. Lancet 2005, 366:29-36.
11. Giles MF, Rothwell PM Systematic review and pooled analysis of published and unpublished validations of the ABCD and ABCD2 transient ischemic attack risk scores. Stroke 2010, 41:667-673.
12. Chandratheva A, Geraghty OC, Luengo-Fernandez R, Rothwell PM ABCD2 score predicts severity rather than risk of early recurrent events after transient ischemic attack. Stroke 2010, 41:851-856. the Oxford Vascular Study.
13. Lovett JK, Coull A, Rothwell PM Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology 2004, 62:569-573. the Oxford Vascular Study.
14. Ay H, Gungor L, Arsava EM, et al. A score to predict early risk of recurrence after ischemic stroke. Neurology 2010, 74:128-135.
15. Rothwell PM, Eliasziw M, Gutnikov SA, Warlow CP, Barnett HJ Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet 2004, 363:915-924. the Carotid Endarterectomy Trialists Collaboration.
16. Gulli G, Marquardt L, Rothwell PM, Markus HS Stroke risk after posterior circulation stroke/transient ischemic attack and its relationship to site of vertebrobasilar stenosis: pooled data analysis from prospective studies. Stroke 2013, 44:598-604.
17. 2 clinical prediction rule: a systematic review and meta-analysis. Fam Pract 2011, 28:366-376.
18. Amarenco P, Labreuche J, Lavallée PC Patients with transient ischemic attack with ABCD2 <4 can have similar 90-day stroke risk as patients with transient ischemic attack with ABCD2 ≥4. Stroke 2012, 43:863-865.
19. 2 score to identify patients at early risk of stroke after transient ischaemic attack: a multicentre observational study. Lancet Neurol 2010, 9:1060-1069.
20. Redgrave JN, Coutts SB, Schulz UG, Briley D, Rothwell PM Systematic review of associations between the presence of acute ischemic lesions on diffusion-weighted imaging and clinical predictors of early stroke risk after transient ischemic attack. Stroke 2007, 38:1482-1488.
21. Al-Khaled M, Eggers J MRI findings and stroke risk in TIA patients with different symptom durations. Neurology 2013, 80:1920-1926.
22. Song B, Fang H, Zhao L, et al. Validation of the ABCD3-I score to predict stroke risk after transient ischemic attack. Stroke 2013, 44:1244-1248.
23. Miyagi T, Uehara T, Kimura K, et al. Examination timing and lesion patterns in diffusion-weighted magnetic resonance imaging of patients with classically defined transient ischemic attack. J Stroke Cerebrovasc Dis 2013, published online Jan 22. 10.1016/j.jstrokecerebrovasdis.2012.12.007.
24. Arsava EM, Furie KL, Schwamm LH, Sorensen AG, Ay H Prediction of early stroke risk in transient symptoms with infarction: relevance to the new tissue-based definition. Stroke 2011, 42:2186-2190.
25. Sandercock PAG, Counsell C, Gubitz GJ, Tseng MC Antiplatelet therapy for acute ischaemic stroke. Cochrane Database Syst Rev 2008, 3. CD000029.
26. Wong KS, Wang Y, Leng X, et al. Early dual versus mono antiplatelet therapy for acute non-cardioembolic ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis. Circulation 2013, 128:1656-1666.
27. Rerkasem K, Rothwell PM Carotid endarterectomy for symptomatic carotid stenosis. Cochrane Database Syst Rev 2011, 4. CD001081.
28. Bonati LH, Lyrer P, Ederle J, Featherstone R, Brown MM Percutaneous transluminal balloon angioplasty and stenting for carotid artery stenosis. Cochrane Database Syst Rev 2012, 9. CD000515.
29. Rothwell PM, Giles MF, Chandratheva A, et al. Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. Lancet 2007, 370:1432-1442. the Early use of Existing Preventive Strategies for Stroke (EXPRESS) study.
30. Algra A, van Gijn J Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin. J Neurol Neurosurg Psychiatry 1999, 66:255.
31. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009, 373:1849-1860. the Antithrombotic Trialists' (ATT) Collaboration.
32. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996, 348:1329-1339. CAPRIE Steering Committee.
33. Sudlow CL, Mason G, Maurice JB, Wedderburn CJ, Hankey GJ Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. Cochrane Database Syst Rev 2009, 4. CD001246.
34. Halkes PHA, Gray LJ, Bath PMW, et al. Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: a meta-analysis by risk. J Neurol Neurosurg Psychiatry 2008, 79:1218-1223.
35. Sacco RL, Diener H-C, Yusuf S, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008, 359:1238-1251. the PRoFESS Study Group.
36. Dinicolantonio JJ, Lavie CJ, Fares H, et al. Meta-analysis of cilostazol versus aspirin for the secondary prevention of stroke. Am J Cardiol 2013, published online July 2. 10.1016/j.amjcard.2013.05.067.
37. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993, 342:1255-1262. EAFT (European Atrial Fibrillation Trial) Study Group.
38. Saxena R, Koudstaal PJ Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischaemic attack. Cochrane Database Syst Rev 2004, 2. CD000185.
39. Ntaios G, Papavasileiou V, Diener HC, Makaritsis K, Michel P Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials. Stroke 2012, 43:3298-3304.
40. Liu L, Wang Z, Gong L, et al. Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertens Res 2009, 32:1032-1040.
41. Law MR, Morris JK, Wald NJ Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009, 338:b1665.
42. Amarenco P, Labreuche J Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 2009, 8:453-463.
43. Lavallée PC, Meseguer E, Abboud H, et al. A transient ischaemic attack clinic with round-the-clock access (SOS-TIA): feasibility and effects. Lancet Neurol 2007, 6:953-960.
44. Wardlaw JM, Murray V, Berge E, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 2012, 379:2364-2372.
45. Patrono C, Andreotti F, Arnesen H, et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J 2011, 32:2922-2932.
46. Sandercock PA, Counsell C, Kamal AK Anticoagulants for acute ischaemic stroke. Cochrane Database Syst Rev 2008, 4. CD000024.
47. Whiteley WN, Adams HP, Bath PM, et al. Targeted use of heparin, heparinoids, or low-molecular-weight heparin to improve outcome after acute ischaemic stroke: an individual patient data meta-analysis of randomised controlled trials. Lancet Neurol 2013, 12:539-545.
48. Paciaroni M, Agnelli G, Micheli S, Caso V Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. Stroke 2007, 38:423-430.
49. Hankey GJ Unanswered questions and research priorities to optimise stroke prevention in atrial fibrillation with the new oral anticoagulants. Thromb Haemost 2013, published online Nov 28. http://dx.doi.org/10.1160/TH13-09-0741.
50. Bonati LH, Fraedrich G Age modifies the relative risk of stenting versus endarterectomy for symptomatic carotid stenosis-a pooled analysis of EVA-3S, SPACE, and ICSS. Eur J Vasc Endovasc Surg 2011, 41:153-158. the Carotid Stenting Trialists' Collaboration.
51. Álvarez-Sabín J, Maisterra O, Santamarina E, Kase CS Factors influencing haemorrhagic transformation in ischaemic stroke. Lancet Neurol 2013, 12:689-705.
52. Johnston SC, Easton JD, Farrant M, et al. Platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trial: rationale and design. Int J Stroke 2013, 8:479-483.
53. Triple antiplatelets for reducing dependency after ischemic stroke (TARDIS). (accessed April 18, 2013). http://clinicaltrials.gov/show/NCT01661322.
54. Aradi D, Komócsi A, Vorobcsuk A, Serebruany VL Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Thromb Haemost 2013, 109:93-101.
55. Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012, 366:9-19. the ATLAS ACS 2-TIMI 51 Investigators.
56. Bekelis K, Bakhoum SF, Desai A, Mackenzie TA, Goodney P, Labropoulos N A risk factor-based predictive model of outcomes in carotid endarterectomy: the National Surgical Quality Improvement Program 2005-2010. Stroke 2013, 44:1085-1090.
57. Strömberg S, Gelin J, Osterberg T, Bergström GM, Karlström L, Osterberg K Very urgent carotid endarterectomy confers increased procedural risk. Stroke 2012, 43:1331-1335. the Swedish Vascular Registry (Swedvasc) Steering Committee.
58. Rantner B, Goebel G, Bonati LH, Ringleb PA, Mas JL, Fraedrich G The risk of carotid artery stenting compared with carotid endarterectomy is greatest in patients treated within 7 days of symptoms. J Vasc Surg 2013, 57:619-626. the Carotid Stenting Trialists' Collaboration, e2, discussion 625-26.
59. Wimmer NJ, Yeh RW, Cutlip DE, Mauri L Risk prediction for adverse events after carotid artery stenting in higher surgical risk patients. Stroke 2012, 43:3218-3224.
60. Lal BK, Beach KW, Roubin GS, et al. Restenosis after carotid artery stenting and endarterectomy: a secondary analysis of CREST, a randomised controlled trial. Lancet Neurol 2012, 11:755-763. the CREST Investigators.
61. Shahidi S, Owen-Falkenberg A, Hjerpsted U, Rai A, Ellemann K Urgent best medical therapy may obviate the need for urgent surgery in patients with symptomatic carotid stenosis. Stroke 2013, 44:2220-2225.
62. Chaturvedi S Aggressive medical therapy alone is adequate in certain patients with severe symptomatic carotid stenosis. Stroke 2013, 44:2955-2956.
63. Chimowitz MI, Lynn MJ, Derdeyn CP, et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med 2011, 365:993-1003. the SAMMPRIS trial investigators.
64. Miao Z, Jiang L, Wu H, et al. Randomized controlled trial of symptomatic middle cerebral artery stenosis: endovascular versus medical therapy in a Chinese population. Stroke 2012, 43:3284-3290.
65. Hankey G, Warlow C Prognosis of symptomatic carotid occlusion: an overview. Cerebrovasc Dis 1991, 1:245-256.
66. Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke. Results of an international randomized trial. N Engl J Med 1985, 313:1191-1200. The EC/IC Bypass Study Group.
67. Powers WJ, Clarke WR, Grubb RL, Videen TO, Adams HP, Derdeyn CP Extracranial-intracranial bypass surgery for stroke prevention in hemodynamic cerebral ischemia: the Carotid Occlusion Surgery Study randomized trial. JAMA 2011, 306:1983-1992. the COSS Investigators.
68. Stayman AN, Nogueira RG, Gupta R A systematic review of stenting and angioplasty of symptomatic extracranial vertebral artery stenosis. Stroke 2011, 42:2212-2216.
69. Vertebral Ischemia Stenting Trial (VIST), (accessed Nov 27, 2013). http://www.controlled-trials.com/ISRCTN95212240/VIST.
70. Vertebral Artery Stenting Trial (VAST), (accessed Nov 27, 2013). http://www.controlled-trials.com/ISRCTN29597900.
71. Merwick A, Albers GW, Arsava EM, et al. Reduction in early stroke risk in carotid stenosis with transient ischemic attack associated with statin treatment. Stroke 2013, 44:2814-2820.
72. Kennedy J, Hill MD, Ryckborst KJ, Eliasziw M, Demchuk AM, Buchan AM Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol 2007, 6:961-969. the FASTER Investigators.
73. Beer C, Blacker D, Bynevelt M, Hankey GJ, Puddey IB A randomized placebo controlled trial of early treatment of acute ischemic stroke with atorvastatin and irbesartan. Int J Stroke 2012, 7:104-111.
74. Morrissey RP, Diamond GA, Kaul S Statins in acute coronary syndromes: do the guideline recommendations match the evidence?. J Am Coll Cardiol 2009, 54:1425-1433.
75. Robinson TG, Potter JF, Ford GA, et al. Effects of antihypertensive treatment after acute stroke in the Continue or Stop Post-Stroke Antihypertensives Collaborative Study (COSSACS): a prospective, randomised, open, blinded-endpoint trial. Lancet Neurol 2010, 9:767-775. the COSSACS Investigators.
76. Sandset EC, Bath PMW, Boysen G, et al. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet 2011, 377:741-750. the SCAST Study Group.
77. Mohan KM, Wolfe CD, Rudd AG, Heuschmann PU, Kolominsky-Rabas PL, Grieve AP Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysis. Stroke 2011, 42:1489-1494.
78. Rutten-Jacobs LC, Maaijwee NA, Arntz RM, et al. Long-term risk of recurrent vascular events after young stroke: the FUTURE study. Ann Neurol 2013, published online June 17. 10.1002/ana.23953.
79. Mohan KM, Crichton SL, Grieve AP, Rudd AG, Wolfe CD, Heuschmann PU Frequency and predictors for the risk of stroke recurrence up to 10 years after stroke: the South London Stroke Register. J Neurol Neurosurg Psychiatry 2009, 80:1012-1018.
80. Paul NL, Simoni M, Chandratheva A, Rothwell PM Population-based study of capsular warning syndrome and prognosis after early recurrent TIA. Neurology 2012, 79:1356-1362.
81. Purroy F, Jiménez Caballero PE, Gorospe A, et al. Recurrent transient ischaemic attack and early risk of stroke: data from the PROMAPA study. J Neurol Neurosurg Psychiatry 2013, 84:596-603. the Stroke Project of the Spanish Cerebrovascular Diseases Study Group.
82. Ois A, Cuadrado-Godia E, Rodríguez-Campello A, et al. Relevance of stroke subtype in vascular risk prediction. Neurology 2013, 81:575-580.
83. Charidimou A, Kakar P, Fox Z, Werring DJ Cerebral microbleeds and recurrent stroke risk: systematic review and meta-analysis of prospective ischemic stroke and transient ischemic attack cohorts. Stroke 2013, 44:995-1001.
84. Weimar C, Benemann J, Michalski D, et al. Prediction of recurrent stroke and vascular death in patients with transient ischemic attack or nondisabling stroke: a prospective comparison of validated prognostic scores. Stroke 2010, 41:487-493. the German Stroke Study Collaboration.
85. Lemmens R, Smet S, Thijs VN Clinical scores for predicting recurrence after transient ischemic attack or stroke: how good are they?. Stroke 2013, 44:1198-1203.
86. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 2010, 137:263-272.
87. Olesen JB, Lip GY, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011, 342:d124.
88. Albertsen IE, Rasmussen LH, Overvad TF, Graungaard T, Larsen TB, Lip GY Risk of stroke or systemic embolism in atrial fibrillation patients treated with warfarin: a systematic review and meta-analysis. Stroke 2013, 44:1329-1336.
89. 2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med 2011, 155:660-667. the RE-LY Investigators.
90. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010, 138:1093-1100.
91. McGrath ER, Kapral MK, Fang J, et al. Which risk factors are more associated with ischemic stroke than intracerebral hemorrhage in patients with atrial fibrillation?. Stroke 2012, 43:2048-2054. the Investigators of the Registry of the Canadian Stroke Network.
92. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006, 354:1706-1717. the CHARISMA Investigators.
93. Benavente OR, Hart RG, McClure LA, Szychowski JM, Coffey CS, Pearce LA Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med 2012, 367:817-825. the SPS3 Investigators.
94. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004, 364:331-337. the MATCH investigators.
95. Lee M, Saver JL, Hong KS, Rao NM, Wu YL, Ovbiagele B Risk-benefit profile of long-term dual- versus single-antiplatelet therapy among patients with ischemic stroke: a systematic review and meta-analysis. Ann Intern Med 2013, 159:463-470.
96. Saxena R, Koudstaal PJ Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack. Cochrane Database Syst Rev 2004, 4. CD000187.
97. Healey JS, Hart RG, Pogue J, et al. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W). Stroke 2008, 39:1482-1486.
98. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151. the RE-LY Steering Committee and Investigators.
99. Diener H-C, Connolly SJ, Ezekowitz MD, et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol 2010, 9:1157-1163. the RE-LY study group.
100. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011, 365:981-992. the ARISTOTLE Committees and Investigators.
101. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011, 364:806-817. the AVERROES Steering Committee and Investigators.
102. Easton JD, Lopes RD, Bahit MC, et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol 2012, 11:503-511. the ARISTOTLE Committees and Investigators.
103. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365:883-891. the ROCKET AF Investigators.
104. Hankey GJ, Patel MR, Stevens SR, et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol 2012, 11:315-322. the ROCKET AF Steering Committee Investigators.
105. Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013, 381:1107-1115. the WOEST study investigators.
106. Lamberts M, Gislason GH, Olesen JB, et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol 2013, 62:981-989.
107. Webb AJS, Fischer U, Mehta Z, Rothwell PM Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet 2010, 375:906-915.
108. Benavente OR, Coffey CS, Conwit R, et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet 2013, 382:507-515. the SPS3 Study Group.
109. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681. the Cholesterol Treatment Trialists' (CTT) Collaboration.
110. Amarenco P, Benavente O, Goldstein LB, et al. Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes. Stroke 2009, 40:1405-1409. the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators.
111. Amarenco P, Goldstein LB, Szarek M, et al. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2007, 38:3198-3204. the SPARCL Investigators.
112. O'Donnell MJ, Xavier D, Liu L, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet 2010, 376:112-123. the INTERSTROKE investigators.
113. Kim J, Gall SL, Dewey HM, Macdonell RAL, Sturm JW, Thrift AG Baseline smoking status and the long-term risk of death or nonfatal vascular event in people with stroke: a 10-year survival analysis. Stroke 2012, 43:3173-3178.
114. Cahill K, Stevens S, Perera R, Lancaster T Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev 2013, 5. CD009329.
115. He FJ, Li J, Macgregor GA Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomised trials. BMJ 2013, 346:f1325.
116. Hankey GJ Nutrition and the risk of stroke. Lancet Neurol 2012, 11:66-81.
117. Grosser T, Fries S, Lawson JA, Kapoor SC, Grant GR, FitzGerald GA Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation 2013, 127:377-385.
118. Costa J, Ferro JM, Matias-Guiu J, Alvarez-Sabin J, Torres F Triflusal for preventing serious vascular events in people at high risk. Cochrane Database Syst Rev 2005, 3. CD004296.
119. Bousser MG, Amarenco P, Chamorro A, et al. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet 2011, 377:2013-2022. the PERFORM Study Investigators.
120. Morrow DA, Alberts MJ, Mohr JP, et al. Efficacy and safety of vorapaxar in patients with prior ischemic stroke. Stroke 2013, 44:691-698. the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-TIMI 50 Steering Committee and Investigators.
121. De Schryver EL, Algra A, Kappelle LJ, van Gijn J, Koudstaal PJ Vitamin K antagonists versus antiplatelet therapy after transient ischaemic attack or minor ischaemic stroke of presumed arterial origin. Cochrane Database Syst Rev 2012, 9. CD001342.
122. Connolly SJ, Eikelboom JW, Ng J, et al. Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. Ann Intern Med 2011, 155:579-586. the ACTIVE (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) Steering Committee and Investigators.
123. Cochrane handbook for systematic reviews of interventions, version 5.1.0 2011, The Cochrane Collaboration, (accessed Nov 27, 2013). http://handbook.cochrane.org, J.P.T. Higgins, S. Green (Eds.).
124. Banerjee A, Lane DA, Torp-Pedersen C, Lip GY Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost 2012, 107:584-589.
125. Schiele F, van Ryn J, Canada K, et al. A specific antidote for dabigatran: functional and structural characterization. Blood 2013, 121:3554-3562.
126. Lu G, DeGuzman FR, Hollenbach SJ, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013, 19:446-451.
127. Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009, 374:534-542. the PROTECT AF Investigators.
128. Almekhlafi MA, Wilton SB, Rabi DM, Ghali WA, Lorenzetti DL, Hill MD Recurrent cerebral ischemia in medically treated patent foramen ovale: a meta-analysis. Neurology 2009, 73:89-97.
129. Mas JL, Arquizan C, Lamy C, et al. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 2001, 345:1740-1746. the Patent Foramen Ovale and Atrial Septal Aneurysm Study Group.
130. Furlan AJ, Reisman M, Massaro J, et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med 2012, 366:991-999. the CLOSURE I Investigators.
131. Carroll JD, Saver JL, Thaler DE, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med 2013, 368:1092-1100. the RESPECT Investigators.
132. Meier B, Kalesan B, Mattle HP, et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med 2013, 368:1083-1091. the PC Trial Investigators.
133. Wolfrum M, Froehlich GM, Knapp G, et al. Stroke prevention by percutaneous closure of patent foramen ovale: a systematic review and meta-analysis. Heart 2013, published online June 21. 10.1136/heartjnl-2013-304394.
134. Aburto NJ, Hanson S, Gutierrez H, Hooper L, Elliott P, Cappuccio FP Effect of increased potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses. BMJ 2013, 346:f1378.
135. Ziv A, Vogel O, Keret D, et al. Comprehensive approach to Lower Blood Pressure (CALM-BP): a randomized controlled trial of a multifactorial lifestyle intervention. J Hum Hypertens 2013, 27:594-600.
136. Rothwell PM, Howard SC, Dolan E, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010, 375:895-905.
137. McKinney JS, Kostis WJ Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials. Stroke 2012, 43:2149-2156.
138. Goldstein LB, Amarenco P, Szarek M, et al. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology 2008, 70:2364-2370. the SPARCL Investigators.
139. Amarenco P, Goldstein LB, Messig M, et al. Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial. Stroke 2009, 40:2486-2492. the SPARCL Investigators.
140. Morrone D, Weintraub WS, Toth PP, et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis 2012, 223:251-261.
141. Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008, 358:1431-1443. the ENHANCE Investigators.
142. Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 2012, 380:29-36.
143. Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation 2012, 126:2408-2417.
144. Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 2012, 308:2497-2506.
145. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012, 367:2089-2099. the dal-OUTCOMES Investigators.
146. Teo KK, Goldstein LB, Chaitman BR, et al. Extended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) trial. Stroke 2013, 44:2688-2693. the AIM-HIGH Investigators.
147. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013, 34:1279-1291. HPS2-THRIVE Collaborative Group.
148. The National Lipid Association statement on use of niacin in light of HPS2-THRIVE presentation on March 9, 2013 (accessed May 31, 2013). https://www.lipid.org/nla/nla-statement-use-niacin-light-hps2-thrive-presentation-march-9-2013.
149. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011, 343:d4169.
150. Martí-Carvajal AJ, Solà I, Lathyris D, Karakitsiou DE, Simancas-Racines D Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev 2013, 1. CD006612. 10.1002/14651858.CD006612.pub3.
151. Holmes MV, Newcombe P, Hubacek JA, et al. Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials. Lancet 2011, 378:584-594.
152. Cavalieri M, Schmidt R, Chen C, et al. B vitamins and magnetic resonance imaging-detected ischemic brain lesions in patients with recent transient ischemic attack or stroke: the VITAmins TO Prevent Stroke (VITATOPS) MRI-substudy. Stroke 2012, 43:3266-3270. the VITATOPS Trial Study Group.
153. Hankey GJ, Eikelboom JW, Yi Q, et al. Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a post-hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial. Lancet Neurol 2012, 11:512-520. the VITATOPS trial study group.
154. Hankey GJ Vitamin supplementation and stroke prevention. Stroke 2012, 43:2814-2818.
155. Myung SK, Ju W, Cho B, et al. Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials. BMJ 2013, 346:f10. the Korean Meta-Analysis Study Group.
156. Sare GM, Gray LJ, Bath PMW Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. Eur Heart J 2008, 29:2031-2041.
157. Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012, 345:e6409.
158. Hackam DG, Spence JD Combining multiple approaches for the secondary prevention of vascular events after stroke: a quantitative modeling study. Stroke 2007, 38:1881-1885.
159. Raine R, Wong W, Ambler G, et al. Sociodemographic variations in the contribution of secondary drug prevention to stroke survival at middle and older ages: cohort study. BMJ 2009, 338:b1279.
160. Asberg S, Henriksson KM, Farahmand B, et al. Ischemic stroke and secondary prevention in clinical practice: a cohort study of 14,529 patients in the Swedish Stroke Register. Stroke 2010, 41:1338-1342.
161. Béjot Y, Zeller M, Lorgis L, et al. Secondary prevention in patients with vascular disease. A population based study on the underuse of recommended medications. J Neurol Neurosurg Psychiatry 2013, 84:348-353.
162. Bushnell CD, Olson DM, Zhao X, et al. Secondary preventive medication persistence and adherence 1 year after stroke. Neurology 2011, 77:1182-1190. the AVAIL Investigators.
163. Glader EL, Sjölander M, Eriksson M, Lundberg M Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke. Stroke 2010, 41:397-401.
164. Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011, 378:1231-1243. the Prospective Urban Rural Epidemiology (PURE) Study Investigators.
165. Teo K, Lear S, Islam S, et al. Prevalence of a healthy lifestyle among individuals with cardiovascular disease in high-, middle- and low-income countries: The Prospective Urban Rural Epidemiology (PURE) study. JAMA 2013, 309:1613-1621. the PURE Investigators.
166. O'Carroll R, Whittaker J, Hamilton B, Johnston M, Sudlow C, Dennis M Predictors of adherence to secondary preventive medication in stroke patients. Ann Behav Med 2011, 41:383-390.
167. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008, 2. CD000011.
168. Rahiman A, Saver JL, Porter V, et al. In-hospital initiation of secondary prevention is associated with improved vascular outcomes at 3 months. J Stroke Cerebrovasc Dis 2008, 17:5-8.
169. Joubert J, Reid C, Barton D, et al. Integrated care improves risk-factor modification after stroke: initial results of the Integrated Care for the Reduction of Secondary Stroke model. J Neurol Neurosurg Psychiatry 2009, 80:279-284.
170. Dromerick AW, Gibbons MC, Edwards DF, et al. Preventing recurrence of thromboembolic events through coordinated treatment in the District of Columbia. Int J Stroke 2011, 6:454-460.
171. Goldfinger JZ, Kronish IM, Fei K, et al. Peer education for secondary stroke prevention in inner-city minorities: design and methods of the prevent recurrence of all inner-city strokes through education randomized controlled trial. Contemp Clin Trials 2012, 33:1065-1073.
172. Hohmann C, Neumann-Haefelin T, Klotz JM, Freidank A, Radziwill R Adherence to hospital discharge medication in patients with ischemic stroke: a prospective, interventional 2-phase study. Stroke 2013, 44:522-524.
173. O'Carroll RE, Chambers JA, Dennis M, Sudlow C, Johnston M Improving adherence to medication in stroke survivors: a pilot randomised controlled trial. Ann Behav Med 2013, published online May 14. 10.1007/s12160-013-9515-5.